<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="description" content="drugdevelopR">
<title>Time-to-event outcome Variables • drugdevelopR</title>
<script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet">
<script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous">
<!-- bootstrap-toc --><script src="https://cdn.jsdelivr.net/gh/afeld/bootstrap-toc@v1.0.1/dist/bootstrap-toc.min.js" integrity="sha256-4veVQbu7//Lk5TSmc7YV48MxtMy98e26cf5MrgZYnwo=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Time-to-event outcome Variables">
<meta property="og:description" content="drugdevelopR">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">drugdevelopR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.0.0</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto">
<li class="nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="active nav-item dropdown">
  <a href="#" class="nav-link dropdown-toggle" data-bs-toggle="dropdown" role="button" aria-expanded="false" aria-haspopup="true" id="dropdown-articles">Articles</a>
  <div class="dropdown-menu" aria-labelledby="dropdown-articles">
    <a class="dropdown-item" href="../articles/Introduction-to-drugdevelopR.html">Introduction to planning phase II and phase III trials with drugdevelopR</a>
    <a class="dropdown-item" href="../articles/Package_validation.html">Package validation</a>
    <div class="dropdown-divider"></div>
    <a class="dropdown-item" href="../articles/index.html">More articles...</a>
  </div>
</li>
<li class="nav-item">
  <a class="nav-link" href="../news/index.html">Changelog</a>
</li>
      </ul>
<form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off">
</form>

      <ul class="navbar-nav">
<li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/Sterniii3/drugdevelopR/" aria-label="github">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul>
</div>

    
  </div>
</nav><div class="container template-article">




<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="" class="logo" alt=""><h1>Time-to-event outcome Variables</h1>
            
      
      <small class="dont-index">Source: <a href="https://github.com/Sterniii3/drugdevelopR/blob/HEAD/vignettes/Time-to-event_outcomes.Rmd" class="external-link"><code>vignettes/Time-to-event_outcomes.Rmd</code></a></small>
      <div class="d-none name"><code>Time-to-event_outcomes.Rmd</code></div>
    </div>

    
    
<p>Suppose we are planning a drug development program testing the
superiority of an experimental treatment over a control treatment. Our
drug development program consists of an exploratory phase II trial which
is, in case of promising results, followed by a confirmatory phase III
trial.</p>
<p>The drugdevelopR package enables us to optimally plan such programs
using a utility-maximizing approach. To get a brief introduction, we
presented a very basic example on how the package works in <a href="https://sterniii3.github.io/drugdevelopR/articles/Introduction-to-drugdevelopR.html">Introduction
to planning phase II and phase III trials with drugdevelopR</a>. In the
introduction, the observed outcome variable “tumor growth” was normally
distributed. However, the drugdevelopR package is not only restricted to
normally distributed outcome variables but also binary distributed
outcome variables and a time-to-event outcome variables. In this article
we want explain how the setting with time-to-event variables works.</p>
<div class="section level2">
<h2 id="the-example-setting">The example setting<a class="anchor" aria-label="anchor" href="#the-example-setting"></a>
</h2>
<p>Suppose we are developing a new tumor treatment, <em>exper</em>. The
patient variable that we want to investigate is how long the patient
survives without further progression of the tumor (progression-free
survival). This is a time-to-event outcome variable.</p>
<p>Within our drug development program, we will compare our experimental
treatment <em>exper</em> to the control treatment <em>contro</em>. The
treatment effect measure is given by <span class="math inline">\(\theta
= −\log(HR)\)</span>, which is the negative logarithm of the hazard
ratio <span class="math inline">\(HR\)</span>, which in turn is the
ratio of the hazard rates. The hazard ratio is a little difficult to
understand. A hazard ratio of 0.75 would mean that the momentary rate of
experiencing (the “hazard”) at any point in time is reduced by 75% in
the experimental group.</p>
</div>
<div class="section level2">
<h2 id="applying-the-package-to-the-example">Applying the package to the example<a class="anchor" aria-label="anchor" href="#applying-the-package-to-the-example"></a>
</h2>
<p>After installing the package according to the <a href="https://sterniii3.github.io/drugdevelopR/#Installation">installation
instructions</a>, we can load it using the following code:</p>
<div class="sourceCode" id="cb1"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="kw"><a href="https://rdrr.io/r/base/library.html" class="external-link">library</a></span><span class="op">(</span><span class="va"><a href="https://github.com/Sterniii3/drugdevelopR" class="external-link">drugdevelopR</a></span><span class="op">)</span></span>
<span><span class="co">#&gt; Loading required package: doParallel</span></span>
<span><span class="co">#&gt; Loading required package: foreach</span></span>
<span><span class="co">#&gt; Loading required package: iterators</span></span>
<span><span class="co">#&gt; Loading required package: parallel</span></span>
<span><span class="co">#&gt; Loading required package: progressr</span></span></code></pre></div>
<div class="section level3">
<h3 id="defining-all-necessary-parameters">Defining all necessary parameters<a class="anchor" aria-label="anchor" href="#defining-all-necessary-parameters"></a>
</h3>
<p>In order to apply the package to the setting from our example, we
need to specify the following parameters:</p>
<ul>
<li>
<code>hr1</code> is our hazard ratio. As already explained above, we
assume that our experimental treatment <em>exper</em> leads to a hazard
reduced by 75% compared to the control treatment <em>contro</em>.
Therefore, we set <code>hr1 = 0.75</code>. For now, we will not model
the hazard ratio on any prior distribution. Thus, we will set
<code>fixed = TRUE</code>.</li>
<li>
<code>d2min</code> and <code>d2max</code> specify the minimal and
maximal number of events for the phase II trial. The package will search
for the optimal sample size within this region. For now, we want the
program to search for the optimal sample size in the interval between 20
and 400 events. In addition, we will tell the program to search this
region in steps of four participants at a time by setting
<code>stepd2 = 4</code>.</li>
<li>
<code>hrgomin</code> and <code>hrgomax</code> specify the minimal
and maximal threshold value for the go/no-go decision rule in terms of
the negative logarithm of the hazard ratio. The package will search for
the optimal threshold value within this region. For now, we want the
program to search in the interval between 0.7 and 0.9 while going in
steps of <code>stephrgo = 0.01</code>. Note that the lower bound of the
decision rule set represents the smallest size of treatment effect
observed in phase II allowing to go to phase III, so it can be used to
model the minimally clinically relevant effect size. Moreover, note that
the interval specified above corresponds to the set <span class="math inline">\(\{-\log(0.9), ..., -\log(0.7)\}\)</span>.</li>
<li>
<code>xi2</code> and <code>xi3</code> correspond to the event rates
in phase II and phase III. After calculating the optimal number of
events <code>d2</code> and <code>d3</code>, the event rates are used to
calculate the optimal sample sizes in phase II and III. We assume event
rates of 0.7 in each phase, indicating that 70 events correspond to an
optimal sample size of 100, respectively.</li>
<li>
<code>c02</code> and <code>c03</code> are fixed costs for phase II
and phase III respectively. We will set the phase II costs to 100 and
the phase III costs to 150 (in <span class="math inline">\(10^5\)</span>$), i.e. we have fixed costs of 10
000 000$ in phase II and 15 000 000$ in phase III. Note that the
currency of the input values does not matter, so an input value for
<code>c02</code> of 15 could also be interpreted as fixed costs of 1 500
000€ if necessary.</li>
<li>
<code>c2</code> and <code>c3</code> are the costs in phase II and
phase III per patient. We will set them to be 0.75 in phase II and 0.1
in phase III. Again, these values are given in <span class="math inline">\(10^5\)</span>$, i.e. we have per patient costs of
75 000$ in phase II and 100 000$ in phase III.</li>
<li>
<code>b1</code>, <code>b2</code> and <code>b3</code> are the
expected small, medium and large benefit categories for successfully
launching the treatment on the market for each effect size category in
<span class="math inline">\(10^5\)</span>$. We will define a small
benefit of 1000, a medium benefit of 2000, and a large benefit of 3000.
The effect size categories directly correspond to the treatment effect:
For example, if the treatment effect is between 1 and 0.95 (in terms of
the risk ratio) we have a small treatment effect yielding an expected
benefit of 100 000 000$.</li>
<li>
<code>alpha</code> is the specified one-sided significance level. We
will set <code>alpha = 0.025</code>.</li>
<li>1 - <code>beta</code> is the minimal power that we require for our
drug development program. We will set <code>beta = 0.1</code>, meaning
that we require a power of 90%.</li>
</ul>
<p>As in the setting with normally distributed outcomes, the treatment
effect may be fixed (as in this example) or may be distributed with
respect to a <a href="https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html">prior
distribution</a>. Furthermore, <a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html">all
options</a> to adapt the program to your specific needs are also
available in this setting.</p>
<p>Now that we have defined all parameters needed for our example, we
are ready to feed them to the package. We will use the function
<code><a href="../reference/optimal_tte.html">optimal_tte()</a></code>, which calculates the optimal sample size and
the optimal threshold value for a time-to-event outcome variable.</p>
<div class="sourceCode" id="cb2"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="va">res</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/optimal_tte.html">optimal_tte</a></span><span class="op">(</span>w <span class="op">=</span> <span class="fl">0.3</span>,                               <span class="co"># define parameters for prior</span></span>
<span>   hr1 <span class="op">=</span> <span class="fl">0.75</span>, hr2 <span class="op">=</span> <span class="fl">0.8</span>, id1 <span class="op">=</span> <span class="fl">210</span>, id2 <span class="op">=</span> <span class="fl">420</span>,           <span class="co"># (https://web.imbi.uni-heidelberg.de/prior/)</span></span>
<span>   d2min <span class="op">=</span> <span class="fl">20</span>, d2max <span class="op">=</span> <span class="fl">400</span>, stepd2 <span class="op">=</span> <span class="fl">5</span>,                   <span class="co"># define optimization set for d2</span></span>
<span>   hrgomin <span class="op">=</span> <span class="fl">0.7</span>, hrgomax <span class="op">=</span> <span class="fl">0.9</span>, stephrgo <span class="op">=</span> <span class="fl">0.01</span>,         <span class="co"># define optimization set for HRgo</span></span>
<span>   alpha <span class="op">=</span> <span class="fl">0.025</span>, beta <span class="op">=</span> <span class="fl">0.1</span>, xi2 <span class="op">=</span> <span class="fl">0.7</span>, xi3 <span class="op">=</span> <span class="fl">0.7</span>,        <span class="co"># drug development planning parameters</span></span>
<span>   c2 <span class="op">=</span> <span class="fl">0.75</span>, c3 <span class="op">=</span> <span class="fl">1</span>, c02 <span class="op">=</span> <span class="fl">100</span>, c03 <span class="op">=</span> <span class="fl">150</span>,               <span class="co"># define fixed and variable costs</span></span>
<span>   K <span class="op">=</span> <span class="cn">Inf</span>, N <span class="op">=</span> <span class="cn">Inf</span>, S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,                            <span class="co"># set constraints</span></span>
<span>   steps1 <span class="op">=</span> <span class="fl">1</span>,  stepm1 <span class="op">=</span> <span class="fl">0.95</span>, stepl1 <span class="op">=</span> <span class="fl">0.85</span>,             <span class="co"># define boundary for  effect size categories</span></span>
<span>   b1 <span class="op">=</span> <span class="fl">1000</span>, b2 <span class="op">=</span> <span class="fl">2000</span>, b3 <span class="op">=</span> <span class="fl">3000</span>,                       <span class="co"># define expected benefits</span></span>
<span>   gamma <span class="op">=</span> <span class="fl">0</span>,                                             <span class="co"># assume different/same population structures </span></span>
<span>   fixed <span class="op">=</span> <span class="cn">TRUE</span>,                                          <span class="co"># choose if  effects are fixed or random</span></span>
<span>   skipII <span class="op">=</span> <span class="cn">FALSE</span>,                                        <span class="co"># more parameters</span></span>
<span>   num_cl <span class="op">=</span> <span class="fl">1</span><span class="op">)</span></span></code></pre></div>
</div>
<div class="section level3">
<h3 id="interpreting-the-output">Interpreting the output<a class="anchor" aria-label="anchor" href="#interpreting-the-output"></a>
</h3>
<p>After setting all these input parameters and running the function,
let’s take a look at the output of the program.</p>
<div class="sourceCode" id="cb3"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="va">res</span></span>
<span><span class="co">#&gt; Optimization result:</span></span>
<span><span class="co">#&gt;  Utility: 377.1</span></span>
<span><span class="co">#&gt;  Sample size:</span></span>
<span><span class="co">#&gt;    phase II: 236, phase III: 614, total: 850</span></span>
<span><span class="co">#&gt;  Expected number of events:</span></span>
<span><span class="co">#&gt;    phase II: 165, phase III: 430, total: 595</span></span>
<span><span class="co">#&gt;  Assumed event rate:</span></span>
<span><span class="co">#&gt;    phase II: 0.7, phase III: 0.7</span></span>
<span><span class="co">#&gt;  Probability to go to phase III: 0.81</span></span>
<span><span class="co">#&gt;  Total cost:</span></span>
<span><span class="co">#&gt;    phase II: 277, phase III: 736, cost constraint: Inf</span></span>
<span><span class="co">#&gt;  Fixed cost:</span></span>
<span><span class="co">#&gt;    phase II: 100, phase III: 150</span></span>
<span><span class="co">#&gt;  Variable cost per patient:</span></span>
<span><span class="co">#&gt;    phase II: 0.75, phase III: 1</span></span>
<span><span class="co">#&gt;  Effect size categories (expected gains):</span></span>
<span><span class="co">#&gt;   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000)</span></span>
<span><span class="co">#&gt;  Success probability: 0.62</span></span>
<span><span class="co">#&gt;  Success probability by effect size:</span></span>
<span><span class="co">#&gt;    small: 0.09, medium: 0.29, large: 0.24</span></span>
<span><span class="co">#&gt;  Significance level: 0.025</span></span>
<span><span class="co">#&gt;  Targeted power: 0.9</span></span>
<span><span class="co">#&gt;  Decision rule threshold: 0.86 [HRgo] </span></span>
<span><span class="co">#&gt;  Assumed true effect: 0.75 [hr] </span></span>
<span><span class="co">#&gt;  Treatment effect offset between phase II and III: 0 [gamma]</span></span></code></pre></div>
<p>The program returns a total of sixteen output values and the input
parameters. For now, we will only look at the most important ones:</p>
<ul>
<li>
<code>res$d2</code> is the optimal number of events for phase II and
<code>res$d3</code> the resulting number of events for phase III. We see
that the optimal scenario requires 165 events in phase II and 430 events
in phase III, which correspond to 236 participants in phase II and 614
in phase III.</li>
<li>
<code>res$HRgo</code> is the optimal threshold value for the
go/no-go decision rule. We see that we need a hazard ratio of less than
0.86 in phase II in order to proceed to phase III.</li>
<li>
<code>res$u</code> is the expected utility of the program for the
optimal sample size and threshold value. In our case it amounts to
377.1, i.e. we have an expected utility of 37 710 000$.</li>
</ul>
</div>
</div>
<div class="section level2">
<h2 id="where-to-go-from-here">Where to go from here<a class="anchor" aria-label="anchor" href="#where-to-go-from-here"></a>
</h2>
<p>In this article we introduced the setting, when the outcome is a
time-to-event variable. For more information on how to use the package,
see:</p>
<ul>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/Introduction-to-drugdevelopR.html"><em>Introduction
to drugdevelopR:</em></a> See how the package works in a basic normally
distributed example.</li>
<li>
<em>Different outcomes:</em> Apply it to <a href="https://sterniii3.github.io/drugdevelopR/articles/Binary_outcomes.html">binary
endpoints</a>.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/Interpreting_Output.html"><em>Interpreting
the rest of the output:</em></a> Obtain further details on your drug
development program.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html"><em>Fixed
or prior:</em></a> Model the assumed treatment effect on a prior
distribution.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html"><em>More
parameters:</em></a> Define custom effect size categories. Put
constraints on the optimization by defining maximum costs, the total
expected sample size of the program or the minimum expected probability
of a successful program. Define an expected difference in treatment
effect between phase II and III. Skip phase II.</li>
<li>
<em>Complex drug development programs:</em> Adapt to situations with
<a href="https://sterniii3.github.io/drugdevelopR/articles/Bias_adjustment.html">biased
effect estimators</a>, <a href="https://sterniii3.github.io/drugdevelopR/articles/Multitrial.html">multiple
phase III trials</a>, <a href="https://sterniii3.github.io/drugdevelopR/articles/Multiarm_Trials.html">multi-arm
trials</a>, or <a href="https://sterniii3.github.io/drugdevelopR/articles/Multiple_Endpoints.html">multiple
endpoints</a>.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html#parallel-computing"><em>Parallel
computing:</em></a> Be faster at calculating the optimum by using
parallel computing.</li>
</ul>
</div>
  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside>
</div>



    <footer><div class="pkgdown-footer-left">
  <p></p>
<p>Developed by Stella Erdmann, Johannes Cepicka, Marietta Kirchner, Meinhard Kieser, Lukas D. Sauer.</p>
</div>

<div class="pkgdown-footer-right">
  <p></p>
<p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.7.</p>
</div>

    </footer>
</div>

  

  

  </body>
</html>
